Find a Trial

Trial Results


73 protocol(s) meet the specified criteria
CTO-SNDX-6352-0504OPEN TO ACCRUAL
AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients with Recurrent or Refractory Active Chronic Graft Versus Host Disease who have Received at least 2 Lines of Systemic Therapy
IUCRO-0049OPEN TO ACCRUAL
Immunologic, Genetic, Molecular, and Pathological Correlates with Clinical and Treatment Outcome in Patients with Renal Cell Carcinoma
IUCRO-0280OPEN TO ACCRUAL
IU Simon Cancer Center Tissue Bank
IUSCC-0678OPEN TO ACCRUAL
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
IUSCC-0696OPEN TO ACCRUAL
One-on-one exercise program in adolescent and young adult cancer survivors with a certified clinical cancer exercise specialist
IUSCC-0705OPEN TO ACCRUAL
Informational Meetings for Planning And Coordinating Treatment (IMPACT)
NURS-IUSCC-0720OPEN TO ACCRUAL
Biologic Mechanisms and Dosing of Active Music Engagement in Children with Acute Lymphoblastic Leukemia and Parents
PHO-BAYER-ADVL1721OPEN TO ACCRUAL
A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma
PHO-COG-AALL1731OPEN TO ACCRUAL
Blinatumomab in Combination With Chemotherapy in Treating Patients With or Without Down Syndrome and Newly Diagnosed, Standard Risk B-Lymphoblastic Leukemia or Localized B-Lymphoblastic Lymphoma.
PHO-COG-AALL1732OPEN TO ACCRUAL
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
PHO-COG-AALL1821OPEN TO ACCRUAL
AALL1821, A Phase 2 Study of Blinatumomab (NSC # 765986, IND # 125462) in Combination with Nivolumab (NSC # 748726, IND # 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged equal to or more than 1 to less than 31 Years Old with First Relapse.
PHO-COG-AAML1831OPEN TO ACCRUAL
AAML1831, A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
PHO-COG-AAML18P1OPEN TO ACCRUAL
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
PHO-COG-ACNS1831OPEN TO ACCRUAL
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG).
PHO-COG-ACNS1833OPEN TO ACCRUAL
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
PHO-COG-ACNS1931OPEN TO ACCRUAL
A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
PHO-COG-ACNS2021OPEN TO ACCRUAL
A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor.
PHO-COG-ADVL1823OPEN TO ACCRUAL
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia.
PHO-COG-ADVL18P1OPEN TO ACCRUAL
ADVL18P1, AN OPEN-LABEL FEASIBILITY STUDY TO ASSESS THE SAFETY AND PHARMACOKINETICS OF ENASIDENIB IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R-AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION.
PHO-COG-AGCT1532OPEN TO ACCRUAL
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
PHO-COG-AHEP1531OPEN TO ACCRUAL
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
PHO-COG-ALTE2031OPEN TO ACCRUAL
1169 - ALTE2031, StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors.
PHO-COG-ANBL1531OPEN TO ACCRUAL
A Phase 3 Study of 131-I-Metaiodobenzylguanidine (131-I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
PHO-COG-ANBL1821OPEN TO ACCRUAL
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
PHO-COG-ANBL19P1OPEN TO ACCRUAL
ANBL19P1; A Pilot Study of Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide in the Post-Consolidation Setting for High-Risk Neuroblastoma
PHO-COG-ANHL1931OPEN TO ACCRUAL
A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma.
PHO-COG-AREN1721OPEN TO ACCRUAL
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
PHO-COG-AREN1921OPEN TO ACCRUAL
AREN1921, Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT).
PHO-COG-ARST2031OPEN TO ACCRUAL
A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)
PHO-COG-CROOP-ADVL1822OPEN TO ACCRUAL
A PHASE 1/2, MULTI-CENTER, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH RE-INDUCTION CHEMOTHERAPY, AND AS A SINGLE-AGENT MAINTENANCE THERAPY, IN PEDIATRIC RELAPSED/REFRACTORY AML SUBJECTS AGED 1 MONTH TO < 18 YEARS (AND YOUNG ADULTS AGED UP TO 21 YEARS) WITH FLT3-ITD MUTATIONS
PHO-COG-FALLON-AGCT1531OPEN TO ACCRUAL
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
PHO-COG-FALLON-ALTE03N1OPEN TO ACCRUAL
Key Adverse Events Following Childhood Cancer
PHO-COG-FALLON-ALTE07C1OPEN TO ACCRUAL
ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
PHO-COG-FALLON-ANBL00B1OPEN TO ACCRUAL
Neuroblastoma Biology Studies
PHO-COG-FALLON-ANBL1232OPEN TO ACCRUAL
ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
PHO-COG-FALLON-APEC14B1OPEN TO ACCRUAL
Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
PHO-COG-FALLON-AREN03B2OPEN TO ACCRUAL
Renal Tumors Classification, Biology, and Banking Study
PHO-COG-PEPN1924OPEN TO ACCRUAL
PEPN1924, A Phase 2 Study of DS-8201a (NSC#807708, IND#153036) in Adolescents, or Young Adults with Recurrent HER2+ Osteosarcoma.
PHO-DOD-NF110OPEN TO ACCRUAL
NF110: Open-label, Phase 2 Clinical Trial of Crizotinib for Children and Adults with Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
PHO-EPIZYME-EAPOPEN TO ACCRUAL
Tazemetostat Pediatric Expanded Access Program (EAP). GUIDELINES FOR PEDIATRIC PATIENTS WITH SOLID TUMORS.
PHO-FALLON-COG-AALL1621OPEN TO ACCRUAL
AALL1621, A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
PHO-FALLON-COG-ARST1431OPEN TO ACCRUAL
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
PHO-FALON-INCYTE-AALL1521OPEN TO ACCRUAL
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia
PHO-IIR-COGNITIVE-INTERVENTIONOPEN TO ACCRUAL
Feasibility of a Cognitive Intervention in Pediatric Survivors of Acute Lymphoblastic Leukemia.
PHO-IIR-COVID-19-DISTRESSOPEN TO ACCRUAL
Distress during COVID-19 Pandemic for Caregivers of Children with Hematologic and Oncologic Diagnoses.
PHO-IIR-INFECTIOUSDISEASEOPEN TO ACCRUAL
Infectious Disease Outcomes in Pediatric Oncology Patients.
PHO-IIR-IUSCC-0755OPEN TO ACCRUAL
ANTHROPOMETRIC AND BIOCHEMICAL MARKERS OF NUTRITION IN CHILDREN WITH CANCER: A PILOT INVESTIGATION OF GDF15
PHO-LILLY-JV01-ADVL2021AOPEN TO ACCRUAL
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients andYoung Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
PHO-LILLY-JV02-ADVL2021BOPEN TO ACCRUAL
Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Synovial Sarcoma
PHO-MERCK-KEYNOTE-667OPEN TO ACCRUAL
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
PHO-NCI-SURVIVORLINKOPEN TO ACCRUAL
SurvivorLink: Scalability of an Electronic Personal Health Record for Cancer Survivors and Caregivers at Pediatric Cancer Centers
PHO-NOVARTIS-CCTL019G2201JOPEN TO ACCRUAL
A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy
PHO-NOVARTISMAPS-SKILESOPEN TO ACCRUAL
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
PHO-PBMTC-ENDRADOPEN TO ACCRUAL
A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative
PHO-PFIZER-AAML1921OPEN TO ACCRUAL
Phase I/II study of Bosutinib in pediatric patients with newly diagnosed chronic or resistant/intolerant Ph+ Chronic Myeloid Leukemia.
PHO-PFIZER-PRADHAN-ADVL1921OPEN TO ACCRUAL
PHO-PRADHAN-COG-AALL1631OPEN TO ACCRUAL
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
PHO-PRADHAN-COG-ACNS1422-OPEN TO ACCRUAL
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
PHO-PRADHAN-COG-ADVL1521OPEN TO ACCRUAL
A Phase 2 Study of the MEK Inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
PHO-PRADHAN-COG-ALTE1631OPEN TO ACCRUAL
A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia
PHO-PRADHAN-COG-ALTE16C1OPEN TO ACCRUAL
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
PHO-PRADHAN-COG-APEC1621OPEN TO ACCRUAL
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)MASTER VERSION CONTROL PROTOCOL
PHO-PRADHAN-MERK-ADVL1621OPEN TO ACCRUAL
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
PHO-SEATTLE-PLAT-05OPEN TO ACCRUAL
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22-CAR T Cell Immunotherapy for CD19+CD22+ Leukemia.
PHO-SEATTLE-PLAT-07OPEN TO ACCRUAL
PEDIATRIC AND YOUNG ADULT LEUKEMIA ADOPTIVE THERAPY (PLAT)-07: A PHASE 1/2 STUDY OF CD22-SPECIFIC CAR T CELLS FOR CD22+ LEUKEMIA OR LYMPHOMA
PHO-SHIH-NWC-HEADSTART4OPEN TO ACCRUAL
NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYCLE (LOW RISK PATIENTS) OR RANDOMIZATION (HIGH RISK PATIENTS) TO either SINGLE-CYCLE or TO THREE TANDEM CYCLES OF MARROW-ABLATIVE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE
PHO-STJUDE-AML16OPEN TO ACCRUAL
A PHASE II TRIAL OF EPIGENETIC PRIMING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
PHO-TAKEDA-PON1501-AALL1922OPEN TO ACCRUAL
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
PICU-NIH-BIOSTAROPEN TO ACCRUAL
Biomarkers for susceptibility of Transplant Associated Respiratory failure (BioSTAR).
RAON-STANFORD-AVATAROPEN TO ACCRUAL
AVATAR anesthesia alternative in pediatric radiotherapy: A Multi-Center Pilot Study
S1826OPEN TO ACCRUAL
A PHASE III, RANDOMIZED STUDY OF NIVOLUMAB (OPDIVO) PLUS AVD OR BRENTUXIMAB VEDOTIN (ADCETRIS) PLUS AVD IN PATIENTS (AGE >/= 12 YEARS) WITH NEWLY DIAGNOSED ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA NCT# 03907488
SNEU-IIR-RIMTIHOPEN TO ACCRUAL
Role of Inflammatory Mediators in Tumor-Induced Hydrocephalus
SURG-IIR-COVID-19-RESPONSEOPEN TO ACCRUAL
Impact of the Initial COVID-19 Response and the Following Delayed Care Surge on Patients Requiring Emergent, Urgent, and Elective Surgical Procedures